Drug Profile

Mecobalamin - Eisai

Alternative Names: E 0302; Rozebalamin

Latest Information Update: 27 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eisai Co Ltd
Class Antianaemics; Vitamins
Mechanism of Action Methyltransferase stimulants; Vitamin B 12 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Amyotrophic lateral sclerosis
New Molecular Entity No

Highest Development Phases

Marketed Amyotrophic lateral sclerosis
No development reported Vitamin B deficiency

Most Recent Events

20 Nov 2024 Launched for Amyotrophic lateral sclerosis in Japan (IM)
24 Sep 2024 Registered for Amyotrophic lateral sclerosis in Japan (IM)
28 May 2022 No recent reports of development identified for phase-I development in Vitamin-B-deficiency(In volunteers) in New Zealand (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com